<i>Propionibacterium freudenreichii</i> CIRM-BIA 129 mitigates colitis through S layer protein B-dependent epithelial strengthening-Reference-Cited by-同舟云学术

Propionibacterium freudenreichii CIRM-BIA 129 mitigates colitis through S layer protein B-dependent epithelial strengthening

Published:2024-02-01 Issue:2 Volume:326 Page:G163-G175
ISSN:0193-1857
Container-title:American Journal of Physiology-Gastrointestinal and Liver Physiology
language:en
Short-container-title:American Journal of Physiology-Gastrointestinal and Liver Physiology

Author:

Mantel Marine¹²^ORCID,Durand Tony¹^ORCID,Bessard Anne¹,Pernet Ségolène¹,Beaudeau Julie¹³,Guimaraes-Laguna Juliana²,Maillard Marie-Bernadette²,Guédon Eric²,Neunlist Michel¹,Le Loir Yves²,Jan Gwénaël²,Rolli-Derkinderen Malvyne¹^ORCID

Affiliation:

1. The Enteric Nervous System In Gut And Brain Disorders, IMAD, Institut National de la Santé et de la Recherche Médicale, Nantes Université, Nantes, France

2. Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement, Unité Mixte de Recherche, L’Institut Agro, Rennes, France

3. Centres de Recherche en Nutrition Humaine-Ouest, Nantes, France

Abstract

Propionibacterium freudenreichii reduces dextran sodium sulfate (DSS)-induced intestinal permeability in vivo . P. freudenreichii does not inhibit inflammation but damages linked to inflammation. P. freudenreichii inhibits intestinal epithelial breakdown through S-layer protein B. The protective effects of P. freudenreichii depend on S-layer protein B. Extracellular vesicles from P. freudenreichii CB 129 mimic the protective effect of the probiotic.

Funder

Centres de Recherche en Nutrition Humaine-Ouest

Centre National de la Recherche Scientifique

Conseil Régional de Bretagne

Conseil Régional des Pays de la Loire

Publisher

American Physiological Society

Subject

Physiology (medical),Gastroenterology,Hepatology,Physiology

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpgi.00198.2023

Reference43 articles.

1. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

2. Inflammatory bowel disease therapeutic strategies by modulation of the microbiota: how and when to introduce pre-, pro-, syn-, or postbiotics?

3. Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD

4. Enteric glia at center stage of inflammatory bowel disease

5. Tau accumulates in Crohn's disease gut